Publication date: November 2026 Source: DNA Repair, Volume 167 Author(s): Ronald Feitosa Pinheiro, Roberta Taiane Germano de Oliveira, Renan Victor Brito Aguiar Parente, Antonio Wesley Araújo dos Santos, Carlos Leonardo de Aragão Araújo, Edilson Diogenes Pinheiro Junior, Yuri Vasconcelos Pinheiro
Low-blast SF3B1 myelodysplastic neoplasm shows reduced tolerance to splice-site variants in translesion DNA repair genes. // DNA Repair. – URL: https://www.sciencedirect.com/science/article/pii/S1568786426000583?dgcid=rss_sd_all
Low-blast SF3B1 myelodysplastic neoplasm shows reduced tolerance to splice-site variants in translesion DNA repair genes. DNA Repair. https://www.sciencedirect.com/science/article/pii/S1568786426000583?dgcid=rss_sd_all
“Low-blast SF3B1 myelodysplastic neoplasm shows reduced tolerance to splice-site variants in translesion DNA repair genes.” DNA Repair.
@article{article43549,
title = {Low-blast SF3B1 myelodysplastic neoplasm shows reduced tolerance to splice-site variants in translesion DNA repair genes},
journal = {DNA Repair},
url = {https://www.sciencedirect.com/science/article/pii/S1568786426000583?dgcid=rss_sd_all}
}
Gene Therapy, Published online: 13 November 2026; doi:10.1038/s41434-026-00658-6 Clinical landscape of gene therapy for rare diseases: a registry-based analysis of clinical trials and FDA-approved products
Human Genome Variation, Published online: 12 November 2026; doi:10.1038/s41439-026-00361-3 Arthrogryposis involves multiple joint contractures present at birth, affecting both upper and lower extremities. This study investigates the...
Gene Therapy, Published online: 10 November 2026; doi:10.1038/s41434-026-00657-7 Perspectives on cell and gene therapy: insights from the 5th China Annual Congress on CGT
Gene Therapy, Published online: 04 November 2026; doi:10.1038/s41434-026-00649-7 High-resolution separation and quantification of dual-AAV drug products by density gradient equilibrium analytical ultracentrifugation
Gene Therapy, Published online: 03 November 2026; doi:10.1038/s41434-026-00656-8 Genotoxic safety and long-term engraftment dynamics of efficient translational CRISPR/Cas9 therapeutics for β-haemoglobinopathies from bench to clinical trials